Elicio Therapeutics, Inc. (NASDAQ: ELTX)

Elicio Therapeutics, Inc is a clinical stage biotechnology company focused on developing lymph node targeted immunotherapies for the treatment of cancer. The company uses its proprietary Amphiphile AMP technology to deliver therapeutic payloads to lymph nodes with the goal of generating robust and durable T cell responses against oncogenic drivers such as mutant KRAS BRAF and TP53. Its lead product candidate ELI-002 7P is being evaluated in a Phase 2 trial for mutant KRAS positive pancreatic ductal adenocarcinoma while additional programs targeting BRAF and TP53 driven cancers remain in preclinical stages.

Elicio Therapeutics Inc generates revenue primarily through research grants licensing agreements and potential milestone and royalty payments from collaborators. The company has received funding from the GI Research Foundation to support preclinical development of its ELI-007 and ELI-008 programs. Additionally it holds an exclusive license agreement with MIT that includes obligations for milestone payments and royalties on net sales of licensed products.

Elicio Therapeutics Inc operates in the competitive field of cancer immunotherapy where it faces large pharmaceutical companies and other biotechs developing KRAS targeted therapies such as Amgen's LUMAKRAS and Mirati's KRAZATI. The company differentiates itself through its AMP technology which directs therapeutic agents to lymph nodes to enhance T cell activation and offers off the shelf products based on common neoantigens. This approach aims to overcome limitations of existing therapies that struggle to localize to lymph nodes and generate sufficient anti tumor immunity.

Elicio Therapeutics Inc serves patients enrolled in its clinical trials and collaborates with research institutions and potential pharmaceutical partners to advance its pipeline. The company relies on third party contract manufacturing organizations to produce its drug candidates for preclinical and clinical studies.